Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 28 April - 4 May 2024 and includes updates on cholera, MERS-CoV, SARS-CoV-2, an overview of respiratory virus epidemiology in the EU/EEA, highly pathogenic avian influenza A(H5N1) in cattle and a related human case, Crimean-Congo haemorrhagic fever, and Lassa fever.
Campylobacteriosis is the most frequently reported food- and waterborne disease in the EU/EEA. In 2018, 30 EU/EEA countries reported 250 384 confirmed cases of campylobacteriosis.
For 2020, 29 EU/EEA countries reported 123 062 confirmed cases of campylobacteriosis. This represents a reduction of 26.0% compared with 2019 (UK cases excluded).
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
A prolonged genomic cluster of 20 human Listeria monocytogenes ST1607 infections has been reported. The most recent case was reported in March 2024 in Denmark.
The decline in the reported number of new transmissions of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections across European Union (EU) and European Economic Area (EEA) countries has continued.